Icecure Medical Ltd. Stock Price, News & Analysis

IceCure Medical (Nasdaq: ICCM) announced preliminary unaudited results for 2022, revealing revenue of $3.1 million, down from $4.1 million in 2021, mainly due to a 25% decrease in sales across most territories. The company experienced a 28% increase in U.S. sales. As of December 31, 2022, IceCure's cash and cash equivalents stood at $23.6 million, down from $25.6 million in the previous year. IceCure secured a $3,400 CPT Category III code for breast cancer cryoablation, and interim clinical results showed effectiveness in treating kidney tumors.

IceCure Medical Ltd. (NASDAQ: ICCM) participated in the Society of Interventional Oncology's Annual Scientific Meeting in Washington, D.C., from January 19-23, 2023. The company highlighted its ProSense cryoablation system, which was demonstrated live at their booth. Notable discussions included a panel featuring Dr. Kenneth Tomkovich and Dr. Robert Ward, focusing on cryoablation as a treatment option and the interim results of the ICE3 trial for treating early-stage malignant breast tumors. Dr. Tomkovich emphasized growing interest from radiologists in utilizing ProSense, driven by encouraging trial results and the desire for less invasive treatment options.

IceCure Medical Ltd. (Nasdaq: ICCM) announced its participation in the American Society of Breast Surgeons' Breast Fellows Ultrasound Course on January 13-14, 2023. The event, held in Cincinnati, Ohio, featured hands-on training on the ProSense® System, a minimally invasive cryoablation technology for treating tumors. Dr. Richard Fine led a session on cryoablation, emphasizing the importance of ultrasound training for breast surgeons. CEO Eyal Shamir highlighted the course's success in raising awareness and preparing clinicians for future use of ProSense. The company anticipates a response from the FDA regarding its recent marketing authorization filing for ProSense, aimed at enhancing breast cancer treatment.

IceCure Medical (NASDAQ: ICCM) has announced a Notice of Allowance from the U.S. Patent and Trademark Office for its Cryogen Pump patent, valid until February 2040. This patent, also granted in the European Union and allowed in Japan, supports the development of the next generation of cryoablation systems by enhancing the ProSense® System used in minimally invasive tumor treatments. The novel pump expands capabilities by facilitating a faster cooling rate and operational efficiency, essential for more clinical applications. IceCure's technology aims to provide effective alternatives to traditional surgical methods.

IceCure Medical Ltd. (NASDAQ: ICCM) announced a Notice of Allowance from the Japan Patent Office for its Cryogen Pump patent, effective until 2041. This innovative pump allows longer, multiple cryoablation procedures without needing to refill liquid nitrogen, enhancing clinical applications. The pump improves cooling rates and temperature control for cryoprobes. This patent supports IceCure's distribution agreement with Terumo in Japan, strengthening its market presence. IceCure focuses on advanced cryoablation therapy for treating tumors, including breast and kidney cancers, positioning itself as a leader in minimally invasive treatments.

IceCure Medical Ltd. (Nasdaq: ICCM) issued a letter to shareholders outlining its progress and objectives for 2023. Major achievements in 2022 include raising $14.5 million through equity financing, submitting regulatory requests in the U.S., Canada, and Vietnam, and gaining reimbursement approval for cryoablation procedures. The company aims to enhance its market presence, particularly in breast cancer treatment, and is focused on increasing commercialization efforts globally. CEO Eyal Shamir emphasized confidence in growth and the company's financial stability.

IceCure Medical (Nasdaq: ICCM) has successfully closed its public offering of 8,787,880 ordinary shares at a price of $1.65 per share, generating approximately $14.5 million in gross proceeds. The funds will be used for developing next-generation systems, collecting clinical data, regulatory approvals, and general corporate purposes. A.G.P./Alliance Global Partners served as the lead placement agent for the offering.

IceCure Medical Ltd. (Nasdaq: ICCM) has priced its public offering of 8,787,880 ordinary shares at $1.65 each, aiming to raise approximately $14.5 million before expenses. The funds will be utilized for developing next-generation systems, clinical data collection, regulatory approvals, marketing, and general corporate purposes. The offering is expected to close on December 23, 2022, pending customary conditions. A.G.P./Alliance Global Partners serves as the lead placement agent.

IceCure Medical Ltd. (Nasdaq: ICCM) announced a public offering of its ordinary shares, with all securities offered by the Company. The offering's completion is subject to market conditions, and details regarding size and terms are uncertain. Proceeds will fund the development of next-gen systems, clinical data collection, and regulatory approvals, among other uses. A.G.P./Alliance Global Partners is the lead placement agent. This offering is made under an effective shelf registration statement filed with the SEC.